Practice-changing Impact 4/5
It withdraws multiple long-standing recommendations, contraindicates high-dose methylprednisolone at Level I, lowers the ICP treatment threshold to 22 mm Hg, and redirects seizure and sedation practice for neuro-ICU pharmacists.
Evidence Grade: Moderate
Only the steroid recommendation rests on a high-quality body of evidence; most recommendations derive from low- or moderate-quality Class 2/3 studies with frequent applicability and indirectness limitations.
The 4th Edition abandons the prior model where study class dictated recommendation level, instead grading the overall quality of the body of evidence and applicability. Several prior recommendations were withdrawn as not meeting current evidentiary standards, including the specific mannitol dosing recommendations and the periprocedural intubation-antibiotic recommendation. The ICP treatment threshold was lowered from 20 mm Hg to 22 mm Hg, decompressive craniectomy and CSF drainage were added as new topics, and this is declared the final static edition before transition to a continuously updated 'Living Guidelines' model.
| Recommendation | Class | Level |
|---|---|---|
| The use of steroids is not recommended for improving outcome or reducing ICP. In patients with severe TBI, high-dose methylprednisolone was associated with increased mortality and is contraindicated. | Level I | High-quality body of evidence (1 Class 1, 2 Class 2 RCTs; CRASH trial) |
| Although hyperosmolar therapy may lower intracranial pressure, there was insufficient evidence about effects on clinical outcomes to support a specific recommendation, or to support use of any specific hyperosmolar agent (mannitol vs. hypertonic saline). Prior 3rd Edition mannitol dosing recommendations (0.25-1 g/kg) were not carried forward as they no longer meet Class 3 criteria for this topic. | No recommendation (Levels I, II, III insufficient) | Insufficient (1 Class 2 and Class 3 studies only) |
| Prophylactic use of phenytoin or valproate is not recommended for preventing late post-traumatic seizures. Phenytoin is recommended to decrease the incidence of early PTS (within 7 days of injury) when the overall benefit is felt to outweigh the complications; however, early PTS have not been associated with worse outcomes. There is insufficient evidence to recommend levetiracetam over phenytoin regarding efficacy in preventing early PTS and toxicity. | Level II A | Moderate-quality body of evidence (Class 2 studies, largely indirect) |
| Administration of barbiturates to induce burst suppression as prophylaxis against intracranial hypertension is not recommended. High-dose barbiturate administration is recommended to control elevated ICP refractory to maximum standard medical and surgical treatment, with hemodynamic stability essential before and during therapy. Propofol is recommended for control of ICP but not for improvement in mortality or 6-month outcomes; caution is required as high-dose propofol can produce significant morbidity (propofol infusion syndrome). | Level II B | Low-quality body of evidence (Class 2 studies) |
| Treating ICP above 22 mm Hg is recommended because values above this level are associated with increased mortality. A combination of ICP values and clinical and brain CT findings may be used to make management decisions. | Level II B (threshold) / Level III (combined clinical-CT judgment) | Low-quality body of evidence (1 Class 2 study, N=459) |
| Prolonged prophylactic hyperventilation with PaCO2 of 25 mm Hg or less is not recommended. Hyperventilation is recommended only as a temporizing measure for reduction of elevated ICP and should be avoided during the first 24 hours after injury when cerebral blood flow is often critically reduced. | Level II B | Low-quality body of evidence (1 Class 2 RCT) |
| Low molecular weight heparin (LMWH) or low-dose unfractionated heparin may be used in combination with mechanical prophylaxis; however, there is an increased risk for expansion of intracranial hemorrhage. Pharmacologic prophylaxis may be considered if the brain injury is stable and benefit is felt to outweigh risk. There is insufficient evidence to support recommendations regarding preferred agent, dose, or timing. | Level III | Low-quality body of evidence (Class 3, indirect evidence) |
| Feeding patients to attain basal caloric replacement at least by the fifth day and at most by the seventh day post-injury is recommended to decrease mortality. Transgastric jejunal feeding is recommended to reduce the incidence of ventilator-associated pneumonia. Evidence on intensive (tight) glucose control was inconsistent and insufficient to support a recommendation. | Level II A (timing) / Level II B (transgastric jejunal feeding) | Moderate-quality (timing) to Low-quality (method) body of evidence (Class 2 studies) |
The shift from class-driven to body-of-evidence-driven grading means many familiar recommendations lost formal support, which may create friction with legacy order sets and protocols that pharmacists helped build. The lowered 22 mm Hg ICP threshold and the pending RESCUEicp and BEST:TRIP-related debates require close coordination with neurosurgery and intensivists before protocol edits. Applicability caveats are significant: several pivotal trials were single-country or conducted in low-resource settings, so local translation demands clinical judgment. Because hyperosmolar and DVT-prophylaxis agent selection now lacks a specific endorsed drug, pharmacy-driven protocols must document institutional rationale.
The Committee explicitly re-stated withdrawn 3rd Edition recommendations (mannitol dosing, hyperventilation as temporizing measure, ICP monitoring indications) despite them not meeting current evidence standards, reflecting tension between evidentiary rigor and clinical need. The BEST:TRIP RCT found no superiority of ICP-monitor-guided care over clinical/imaging-guided care, challenging a longstanding paradigm, and generated extensive published debate over applicability given its low-resource setting. Intensive insulin/tight glucose control evidence was conflicting and left without a recommendation. The Committee also universally believes hyperosmolar agents are useful yet could not support this belief with a formal recommendation.
Recommendation-level labels here map the BTF's own Level I/IIA/IIB/III system (not ACC/AHA COR/LOE); evidenceLevel reflects the stated quality of the body of evidence and study class. The guideline notes RESCUEicp results were pending at publication and may alter decompressive craniectomy and ICP-threshold recommendations, verify against any subsequent BTF Living Guidelines updates before clinical application.
Full text source: Drive Upload – Management_of_Severe_TBI_4th_Edition.pdf